Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real World Evidence For Cognitive Impairment in the Long Term Care Insurance Population
Aging, Dementia, and Behavioral Neurology
P1 - Poster Session 1 (12:00 PM-1:00 PM)
10-006

Understanding the needs of patients with cognitive impairment is critical to making decisions regarding financial allocations required for their care by long term care insurance (LTCI). 


Introducing structure, standardization and evidence-based protocols commonly used in medicine to qualify the cognitive status of patients enables carriers to accurately discern the cognitive needs of patients and in turn, calculate the cost of care required for patients with neurodegenerative conditions such as Parkinson’s disease, Alzheimer’s disease and related dementias.

As part of a claims processing workflow, Neurocern’s proprietary digital assessment was introduced to capture hundreds of neurological elements relevant to clinical qualification of needs in the context of adjudication requirements for LTCI. Caregivers were qualified by the claims team to accurately report on the patient’s condition. Data quality was ensured using Neurocern’s proprietary disease monitoring algorithms. Caregivers completed questions related to symptoms and diagnoses using a mobile, desktop, or tablet interface. 


Neurocern’s assessments (63% female, 37% male) were analyzed alongside traditional claims processes during a three month intervention, in which carriers qualified the symptom and diagnosis-based information provided through the Neurocern assessment with medical records and face-to-face assessments. The assessments came from claims across the United States from a population of patients with a median income of $100,617. Caregivers had a 100% completion rate and Neurocern correctly identified utilization patterns for patients by using established medical guidelines to accurately assess and determine cognitive-based needs. 

 


Capturing real-world evidence about cognitive impairment in a population actively seeking care support provides opportunities to better understand the functional and behavioral nuances of patients experiencing life changes from complex neurological conditions. Contextualizing real world datasets with accepted medical guidelines provides policymakers, insurance carriers, and pharmaceutical companies with reliable insights into the prognostication and long-term monitoring of complex neurodegenerative diseases.


Authors/Disclosures
Anitha Rao, MD
PRESENTER
An immediate family member of Dr. Rao has received personal compensation for serving as an employee of Abbvie. Dr. Rao has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Neurovision. Dr. Rao has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Virtusense. Dr. Rao has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Eisai. An immediate family member of Dr. Rao has stock in Abbvie. Dr. Rao has a non-compensated relationship as a Executive Board of Directors with Lewy Body Dementia Association that is relevant to AAN interests or activities.
Neelum T. Aggarwal, MD (Rush Alzheimer's Disease Center) Dr. Aggarwal has nothing to disclose.